Supplementary Information:

Participants received approved-label dosing of assigned treatments by subcutaneous injection. All patients randomised to IXE received a 160 mg starting dose (two 80 mg injections) at week 0. IXE-treated patients received 80 mg IXE every 4 weeks from week 4 onwards unless they met criteria for moderate-to-severe psoriasis, in which case they received 80 mg IXE every 2 weeks from week 2 to week 12, followed by IXE every 4 weeks. Patients randomised to ADA received a 40 mg starting dose followed by 40 mg ADA every 2 weeks starting at week 2, or if they met criteria for moderate-to-severe psoriasis, they received an 80 mg starting dose of ADA (two 40 mg injections) at week 0, followed by 40 mg ADA every 2 weeks starting at week 1. Citrate-free formulation of ADA was administered in the study.